论文部分内容阅读
目的评价131Ⅰ治疗分化型甲状腺癌(DTC)的疗效观察。方法对25例术后病理为分化型甲状腺癌的患者进行131Ⅰ治疗,并服用甲状腺素片替代疗法的联合治疗方法,随访1～5年,按照病理类型、服碘次数、转移情况、显像情况等进行疗效分析。结果 25例分化型甲状腺癌患者经1次131Ⅰ治疗,完全清除残留甲状腺15例,不完全清除10例。合并转移患者15例,131Ⅰ治疗后治愈或好转14例。结论分化型甲状腺癌术后应用131Ⅰ治疗,对于清除剩余甲状腺组织、治疗转移灶、降低复发率、延长患者生存期起到重要作用。
Objective To evaluate the therapeutic effect of 131 Ⅰ on differentiated thyroid carcinoma (DTC). Methods Twenty-five patients with pathologically differentiated thyroid cancer were treated with 131 Ⅰ therapy and combined with thyroid hormone replacement therapy. The patients were followed up for 1 to 5 years. According to the pathological type, the frequency of iodine intake, metastasis and imaging Efficacy analysis. Results Twenty-five patients with differentiated thyroid cancer underwent 131 I treatment. Fifteen patients with residual thyroid gland were completely eliminated and 10 patients were not completely eliminated. Fifteen patients with combined metastasis and 131 I treatment were cured or improved in 14 cases. Conclusion The application of 131 Ⅰ after operation in differentiated thyroid cancer patients plays an important role in removing residual thyroid tissue, treating metastases, reducing the recurrence rate and prolonging the survival of patients.